Sanofi/Regeneron’s Libtayo set for new skin cancer use

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings from a phase 2 trial in a hard to treat group of skin cancer patients.